Paris – Mayer Brown advises SERB Pharmaceuticals in connection with the agreement entered into with Hansa Biopharma AB under which SERB will acquire the exclusive development and commercialization rights to Idefirix® (Imlifidase) in the European Union, the United Kingdom, Switzerland, Norway, Liechtenstein, Iceland and the Middle East and North Africa (MENA) region from Hansa.
Idefirix® is a differentiated treatment for the desensitization of highly sensitized adult patients awaiting kidney transplantation.
SERB Pharmaceuticals is a fast-growing global specialty pharma company designed to address rare and urgent conditions by delivering life-saving medicines when time and complexity leave no room for failure.
Completion of the transaction is subject to customary conditions, including required foreign direct investment (FDI) regulatory approval, which is expected to be completed within 60 days.
Mayer Brown advises SERB Pharmaceuticals on the structuring of the transaction with a team led by Tax partner Olivier Parawan, and included counsel Jean-Philippe Coiffard, and Dominique Ehinger.